Singapore - English - HSA (Health Sciences Authority)

lotus international pte. ltd. - ixabepilone - injection, powder, lyophilized, for solution - 15 mg/vial - ixabepilone 15 mg/vial

Singapore - English - HSA (Health Sciences Authority)

lotus international pte. ltd. - ixabepilone - injection, powder, lyophilized, for solution - 45 mg/vial - ixabepilone 45 mg/vial

Kenya - English - Pharmacy and Poisons Board

bayer animal health gmbh 51373 leverkusen nordrhein-westfalen germany - oxytetracycline hydrochloride gentian violet - cutaneous spray - oxytetracycline hydrochloride 40 mg gentian… - all other non-therapeutic veterinary products

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - ixabepilone (unii: k27005np0a) (ixabepilone - unii:k27005np0a) - ixabepilone 15 mg in 15 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mesna - solution for inj/inf - 100 mg/ml - mesna

United States - English - NLM (National Library of Medicine)

recordati rare diseases, inc. - mechlorethamine hydrochloride (unii: l0mr697hhi) (mechlorethamine - unii:50d9xsg0vr) - mechlorethamine hydrochloride 10 mg in 10 ml

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - romidepsin (unii: cx3t89xqbk) (romidepsin - unii:cx3t89xqbk) - romidepsin 10 mg in 2 ml - romidepsin is indicated for the treatment of cutaneous t-cell lymphoma (ctcl) in adult patients who have received at least one prior systemic therapy. romidepsin is indicated for the treatment of peripheral t-cell lymphoma (ptcl) in adult patients who have received at least one prior therapy. this indication is approved under accelerated approval based on response rate [see clinical studies (14.2)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. none. risk summary based on its mechanism of action and findings from animal studies, romidepsin can cause embryo-fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on romidepsin use in pregnant women to inform a drug associated risk of major birth defects and miscarriage. in an animal reproductive study, romidepsin was embryocidal and caused adverse developmental outcomes including embryo-fetal toxicity and malformati

Israel - English - Ministry of Health

megapharm ltd - cyclophosphamide - powder for solution for injection - cyclophosphamide 500 mg/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemic lupus erythematos as which did not respond to other treatment especially with nephritis